Whole CAA cohort (n=130) | CAA with cSAH (n=33) | CAA without cSAH (n=97) | p Value | |
Age at MRI, mean (95% CI), years | 74.2 (72.6 to 75.8) | 73.7 (70.2 to 77.3) | 74.4 (72.6 to 76.2) | 0.715 |
Sex, female, n (%) | 50 (38) | 16 (48) | 17 (18) | 0.171 |
Hypertension, n (%) | 87 (67) | 22 (67) | 65 (67) | 0.971 |
Atrial fibrillation, n (%) | 24 (18) | 3 (9) | 21 (22%) | 0.222 |
Hypercholesterolaemia, n (%) | 71 (55) | 21 (64) | 50 (52) | 0.228 |
Warfarin use, n (%) | 12 (9) | 1 (3) | 11 (11) | 0.298 |
Aspirin use, n (%) | 44 (34) | 10 (30) | 34 (35) | 0.619 |
Statin use, n (%) | 57 (44) | 17 (52) | 40 (41) | 0.304 |
Dementia diagnosis, n (%) | 39 (30) | 5 (15) | 34 (35) | 0.031 |
TFNEs, n (%) | 58 (45) | 25 (76) | 33 (34) | <0.0001 |
*APOE ε2 (1+copies), n (%) | 17 (27) | 6 (35) | 11 (24) | 0.393 |
*APOE ε4 (1+copies), n (%) | 31 (50) | 8 (47) | 23 (51) | 0.776 |
Severe (Fazekas 5–6) WMH, n (%) | 47 (36) | 10 (30) | 37 (38) | 0.418 |
WMH volume, median (IQR), cc | 21.7 (13.4 to 32.3) | 20.3 (12.6 to 32.4) | 24.6 (13.9 to 43.7) | 0.229 |
WMH anteroposterior ratio, (95% CI) | 10.3 (8.4 to 12.2) | 11.2 (8.1 to 14.3) | 10 (7.6 to 12.4) | 0.581 |
Lacunes presence, n (%) | 44 (34) | 8 (24) | 36 (37) | 0.177 |
Moderate/severe atrophy, n (%) | 94 (72) | 22 (67) | 72 (74) | 0.402 |
High-grade CSO-EPVS (>20), n (%) | 74 (57) | 21 (64) | 53 (55) | 0.367 |
Lobar CMBs presence, n (%) | 121 (93) | 30 (91) | 91 (94) | 0.570 |
Lobar CMBs count, median (IQR) | 8 (3–40) | 6 (2–14) | 10 (3–48) | 0.115 |
Logarithm of CMBs count | 2.52 (2.22 to 2.81) | 2.02 (1.56 to 2.49) | 2.68 (2.33 to 3.04) | 0.05 |
Presence of cSS, n (%) | 58 (45) | 27 (82) | 31 (32) | <0.0001 |
Focal cSS, n (%) | 24 (18) | 11 (33) | 13 (13) | <0.0001 |
Disseminated cSS, n (%) | 34 (26) | 16 (48) | 18 (19) | |
Multifocal cSS, n (%) | 38 (29) | 18 (55) | 20 (21) | <0.0001 |
*APOE genotype available in 62 patients.
CAA, cerebral amyloid angiopathy; CSO, centrum semiovale; cSAH, convexity subarachnoid haemorrhage; cSS, cortical superficial siderosis; EPVS, enlarged perivascular spaces; TFNE, transient focal neurological episode.